Zai Lab (NASDAQ:ZLAB) CEO Sells $54,253.85 in Stock

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CEO Ying Du sold 2,653 shares of the firm’s stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $20.45, for a total transaction of $54,253.85. Following the completion of the sale, the chief executive officer owned 1,122,626 shares of the company’s stock, valued at $22,957,701.70. This trade represents a 0.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Ying Du also recently made the following trade(s):

• On Thursday, April 2nd, Ying Du sold 5,576 shares of Zai Lab stock. The stock was sold at an average price of $20.39, for a total transaction of $113,694.64.

Zai Lab Stock Up 1.9%

ZLAB stock traded up $0.39 during trading on Wednesday, hitting $21.39. The company had a trading volume of 1,059,583 shares, compared to its average volume of 745,229. The firm has a market capitalization of $2.41 billion, a P/E ratio of -13.29 and a beta of 0.86. Zai Lab Limited Unsponsored ADR has a 52-week low of $15.96 and a 52-week high of $44.34. The company has a 50 day simple moving average of $18.89 and a 200-day simple moving average of $21.51.

Zai Lab (NASDAQ:ZLAB) last posted its quarterly earnings results on Saturday, February 14th. The company reported ($0.50) EPS for the quarter. The company had revenue of $127.60 million during the quarter. Zai Lab had a negative return on equity of 22.81% and a negative net margin of 38.15%. Sell-side analysts forecast that Zai Lab Limited Unsponsored ADR will post -2.58 earnings per share for the current year.

Institutional Trading of Zai Lab

An institutional investor recently raised its position in Zai Lab stock. SG Americas Securities LLC increased its stake in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 6.6% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,396 shares of the company’s stock after purchasing an additional 642 shares during the period. SG Americas Securities LLC’s holdings in Zai Lab were worth $183,000 as of its most recent filing with the Securities & Exchange Commission. 41.65% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. Zacks Research downgraded shares of Zai Lab from a “hold” rating to a “strong sell” rating in a research report on Friday, January 23rd. JPMorgan Chase & Co. cut their price objective on shares of Zai Lab from $39.00 to $32.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zai Lab in a research report on Wednesday, January 21st. UBS Group assumed coverage on shares of Zai Lab in a research report on Wednesday, January 7th. They issued a “buy” rating and a $35.00 price objective on the stock. Finally, Cantor Fitzgerald cut their price objective on shares of Zai Lab from $55.00 to $37.00 and set an “overweight” rating on the stock in a research report on Friday, February 27th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $50.00.

About Zai Lab

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.